Related references
Note: Only part of the references are listed.Panax notoginseng preparations as adjuvant therapy for diabetic kidney disease: a systematic review and meta-analysis
Xiuge Tang et al.
PHARMACEUTICAL BIOLOGY (2020)
Activation of TRPV1 channel antagonizes diabetic nephropathy through inhibiting endoplasmic reticulum-mitochondria contact in podocytes
Xiao Wei et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2020)
The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation
Jun He et al.
ACTA PHARMACOLOGICA SINICA (2019)
Ginsenoside Rb1 as an Anti-Diabetic Agent and Its Underlying Mechanism Analysis
Ping Zhou et al.
CELLS (2019)
Intravenous formulation of Panax notoginseng root extract: human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions
Salisa Pintusophon et al.
ACTA PHARMACOLOGICA SINICA (2019)
From podocyte biology to novel cures for glomerular disease
Elena Torban et al.
KIDNEY INTERNATIONAL (2019)
Berberine mitigates high glucose-potentiated platelet aggregation and apoptosis by modulating aldose reductase and NADPH oxidase activity
Manoj Paul et al.
FREE RADICAL BIOLOGY AND MEDICINE (2019)
Ginsenoside-Rb1 Improved Diabetic Cardiomyopathy through Regulating Calcium Signaling by Alleviating Protein O-GlcNAcylation
Linhui Qin et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2019)
Ginsenoside Rb1 mitigates oxidative stress and apoptosis induced by methylglyoxal in SH-SY5Y cells via the PI3K/Akt pathway
Fengwei Nan et al.
MOLECULAR AND CELLULAR PROBES (2019)
Ginsenoside Rb1 attenuates diabetic retinopathy in streptozotocin-induced diabetic rats
Changxia Dong et al.
ACTA CIRURGICA BRASILEIRA (2019)
Design, synthesis, structure-activity relationships and X-ray structural studies of novel 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivatives as selective and potent inhibitors of human aldose reductase
Isidro Crespo et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Protective effect of ginsenoside metabolite compound K against diabetic nephropathy by inhibiting NLRP3 inflammasome activation and NF-kappa B/p38 signaling pathway in high-fat diet/streptozotocin-induced diabetic mice
Wu Song et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
Effect of compatible herbs on the pharmacokinetics of effective components of Panax notoginseng in Fufang Xueshuantong Capsule
Huan-huan Pang et al.
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B (2017)
Protein tyrosine phosphatase 1B deficiency in podocytes mitigates hyperglycemia-induced renal injury
Yoshihiro Ito et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2017)
Renoprotective Effects of Aldose Reductase Inhibitor Epalrestat against High Glucose-Induced Cellular Injury
Heba El Gamal et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Panax notoginseng saponins protect kidney from diabetes by up-regulating silent information regulator 1 and activating antioxidant proteins in rats
Du Yue-guang et al.
CHINESE JOURNAL OF INTEGRATIVE MEDICINE (2016)
Diabetes and Kidney Disease: Role of Oxidative Stress
Jay C. Jha et al.
ANTIOXIDANTS & REDOX SIGNALING (2016)
Oxidative stress in chronic vascular disease: From prediction to prevention
Francesca Santilli et al.
VASCULAR PHARMACOLOGY (2015)
Epalrestat increases glutathione, thioredoxin, and heme oxygenase-1 by stimulating Nrf2 pathway in endothelial cells
Kaori Yama et al.
REDOX BIOLOGY (2015)
Molecular mechanisms of diabetic kidney disease
Kimberly Reidy et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Attenuating effect of Fufang Xueshuantong Capsule on kidney function in diabetic nephropathy model
Qian Zhang et al.
JOURNAL OF NATURAL MEDICINES (2013)
Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy
N. Hotta et al.
DIABETIC MEDICINE (2012)
Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy
E. Jennifer Weil et al.
KIDNEY INTERNATIONAL (2012)
Aldose reductase, oxidative stress, and diabetic mellitus
Wai Ho Tang et al.
FRONTIERS IN PHARMACOLOGY (2012)
Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders
Satish K. Srivastava et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2011)
Effects of panax notoginoside on the nephropathy in rats with type 1 diabetes mellitus
Tu Qing-nian et al.
CHINESE JOURNAL OF INTEGRATIVE MEDICINE (2011)
Anti-diabetic effects of Panax notoginseng saponins and its major anti-hyperglycemic components
Chang-yong Yang et al.
JOURNAL OF ETHNOPHARMACOLOGY (2010)
Saponins Isolated from the Root of Panax notoginseng Showed Significant Anti-Diabetic Effects in KK-Ay Mice
Zhong-Hua Chen et al.
AMERICAN JOURNAL OF CHINESE MEDICINE (2008)
Aldose Reductase Genotypes and Cardiorenal Complications An 8-year prospective analysis of 1,074 type 2 diabetic patients
Wing-Yee So et al.
DIABETES CARE (2008)
Ginsenoside Rb1 stimulates glucose uptake through insulin-like signaling pathway in 3T3-L1 adipocytes
Wenbin Shang et al.
JOURNAL OF ENDOCRINOLOGY (2008)
Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy
Masao Toyoda et al.
DIABETES (2007)
Ginsenoside Rb1 promotes adipogenesis in 3T3-L1 cells by enhancing PPARγ2 and C/EBPα gene expression
Wenbin Shang et al.
LIFE SCIENCES (2007)
Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy - The 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial
Nigishi Hotta et al.
DIABETES CARE (2006)
Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients
K Iso et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2001)
Share Paper
